1 DNA Way
South San Francisco
About Genentech, Inc.
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 40 years. Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. We are among the world's leading biotech companies, with multiple products on the market and a promising development pipeline. Please take this opportunity to learn about Genentech where we believe that our employees are our most important asset & are dedicated to remaining a great place to work.
Connect with us!
Being a scientist at Genentech means being a drug discoverer. Mike Varney, head of Genentech Research and Early Development, explains how this culture of innovation is helping to solve some of the hardest biomedical problems of our time.
1437 articles with Genentech, Inc.
Genentech and the Genentech Foundation Commit $42 Million to Address Immediate and Long-Term Effects of the COVID-19 Pandemic
Genentech and the Genentech Foundation are announcing charitable commitments of $42 million to help address the devastating impact of the COVID-19 pandemic.
New Data at the ASCO20 Virtual Scientific Program Reflects Genentech’s Commitment to Accelerating Progress in Cancer Care
First clinical data from tiragolumab, Genentech’s novel anti-TIGIT cancer immunotherapy, in combination with Tecentriq in people with PD-L1-positive metastatic non-small cell lung cancer (NSCLC)
New 6-year Data for Genentech’s Ocrevus (ocrelizumab) Show Earlier Treatment Initiation Nearly Halves Risk of Needing Walking Aid in Relapsing Multiple Sclerosis
Post-hoc analysis from 6 years of Phase III open-label extension studies showed Ocrevus treatment reduced the risk of needing a walking aid (EDSS≥6) by 49% in relapsing multiple sclerosis (RMS) patients compared with patients who switched from interferon beta-1a two years later
Genentech’s Risdiplam Shows Significant Improvement in Survival and Motor Milestones in Infants With Type 1 Spinal Muscular Atrophy (SMA)
FIREFISH Part 2 study met its primary endpoint by demonstrating a significant increase in motor milestones in infants aged 1-7 months after 12 months of treatment
Genentech, a Roche company, presented one-year data from FIREFISH Part 2, its pivotal trial of risdiplam in infants one to seven months old with symptomatic Type 1 spinal muscular atrophy.
This is the 11th FDA approval for Imbruvica across six disease areas and the sixth for the drug in CLL.
Reduces infusion time to 2 hours from the current 3.5 hours for patients with relapsing or primary progressive multiple sclerosis, if approved
Genentech Provides Regulatory Update on Risdiplam for the Treatment of Spinal Muscular Atrophy (SMA)
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the New Drug Application (NDA) of risdiplam with a decision expected by August 24, 2020
Lodo Therapeutics Corp., a biotechnology company applying its proprietary platform to reinvent natural product drug discovery, announced it has achieved a preclinical milestone in its multi-target strategic collaboration with Genentech, a member of the Roche Group.
3/30/2020Although some clinical trials are being slowed or halted, others are reporting out data. Here’s a look.
The application seeks approval of a new, additional formulation of Xofluza as granules for oral suspension for people one year of age and older with influenza
The NDA is for a new formulation of the drug as one-dose granules for oral suspension, would which largely be aimed at children and people who have difficulty swallowing.
BioSpace takes a quick look at some recent, key industry news that is not related to the coronavirus.
Genentech Announces Venclexta Combination Improved Overall Survival in People With Previously Untreated Acute Myeloid Leukemia
Phase III VIALE-A study showed Venclexta plus azacitidine helped people with the most common type of aggressive leukemia in adults live longer compared to azacitidine alone – – Data will be shared with global health authorities and presented at an upcoming medical meeting – SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III VIALE-A study met
Genentech Announces FDA Approval of Clinical Trial for Actemra to Treat Hospitalized Patients With Severe COVID-19 Pneumonia
Genentech announced today the U.S. Food & Drug Administration (FDA) has approved a randomized, double-blind, placebo-controlled Phase III clinical trial i
3/23/2020Here's a look at some of last week's clinical trial news.
A summary of daily Biopharma industry news. Please check out stories that are trending on March 20, 2020.
Genentech Initiates Phase III Clinical Trial of Actemra in Hospitalized Patients With Severe COVID-19 Pneumonia
Genentech announced that the company is working with the U.S. FDA to initiate a randomized, double-blind, placebo-controlled Phase III clinical trial in collaboration with the Biomedical Advanced Research and Development Authority, a part of the U.S. HHS Office of the Assistant Secretary for Preparedness and Response, to evaluate the safety and efficacy of Actemra® plus standard of care in hospitalized adult patients with severe COVID-19 pneumonia compared to placebo plus standard of care.
A summary of daily Biopharma industry news. Please check out stories that are trending on March 19, 2020.
Genentech, Pfizer and Merck Identified as the Top Three Companies Driving Therapeutic Innovation in Breast Cancer
In a recent study conducted by KMK Consulting, Inc., covering Innovation & Customer Value in the Breast Cancer market, Genentech (a member of the Roche Group) was ranked as the top company delivering superior customer value and sales force engagement, as well as delivering therapeutic innovation in this space